Evidence map›Paper›PMID 39781343›Full record

ReviewJournal of Cancer2025

Research Progress of DNA Methylation Markers for Endometrial Carcinoma Diagnosis.

Haoning Zheng, Cuisong Yu, Lu Yang, Fenghua Zhou, Aijun Liu

Abstract readReview
In one paragraph

Review in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. UnveilingTranslational cancer research · 2025
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haoning ZhengClinical Pathology Department, Shandong Second Medical University, Shandong Province, Weifang, Shandong 261042, P.R. China.
Cuisong YuDepartment of Gynecology and Obstetrics of Qingdao West Coast New Area People's Hospital, Shandong Province, Qingdao, Shandong 266000, P.R. China.
Lu YangClinical Pathology Department, Shandong Second Medical University, Shandong Province, Weifang, Shandong 261042, P.R. China.
Fenghua ZhouClinical Pathology Department, Shandong Second Medical University, Shandong Province, Weifang, Shandong 261042, P.R. China.
Aijun LiuDepartment of Pathology, The seventh Medical Center, Chinese PLA General Hospital, Beijing, 100700, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma (EC) is the most common malignancies of the female reproductive system in developed countries and areas. Ultrasound-guided and hysteroscopic samplings are commonly used to diagnose EC. However, clinicians question their diagnostic efficacy and the associated patient discomfort. DNA methylation is the widely studied epigenetic alteration in human tumors, and tumor screening and diagnosis. This review summarized common methods for collecting clinical samples for methylation testing. Furthermore, we analyzed the diagnostic evaluation indices of different methylation marker assays in clinical diagnosis and discussed the challenges of methylation testing in the future application of EC diagnosis.

Indexed as

diagnostic biomarkersDNA methylationendometrial carcinomaepigenetics

Identifiers

PMID39781343
PMCPMC11705058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.